 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Latest Ratings for SGMO
 DateFirmActionFromTo May 2021RBC CapitalInitiates Coverage OnOutperform Jan 2021StifelInitiates Coverage OnHold Dec 2020HC Wainwright & Co.AssumesBuy
 View More Analyst...

What To Know About RBC Capital's Downgrade of Sangamo Therapeutics

Company focuses on neurology-focused genomic medicine, announces restructuring and workforce reductionRelated Stocks: SGMO...

Sangamo Therapeutics Inc (SGMO) Announces Q3 2023 Financial Results and Strategic Update

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced recent business highlights, including progress on its strategic transformation and a corresponding...

Sangamo Therapeutics Announces Strategic Update and Reports Third Quarter 2023 Financial Results

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company has scheduled the release of its third quarter 2023 financial results after the market closes...

Sangamo Therapeutics Announces Third Quarter 2023 Conference Call and Webcast

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the European Society of Gene & Cell Therapy (ESGCT) has accepted six Sangamo abstracts for presentation at...

Sangamo Therapeutics to Present Pre-Clinical Data Showcasing Its Epigenetic Regulation for Neurology and CAR-Treg Research at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced that it will participate in the Jefferies Cell &amp; Genetic Medicine Summit, to be held from September...

Sangamo Therapeutics to Present at the Jefferies Cell & Genetic Medicine Summit

Latest Ratings for SGMO
 DateFirmActionFromTo May 2021RBC CapitalInitiates Coverage OnOutperform Jan 2021StifelInitiates Coverage OnHold Dec 2020HC Wainwright & Co.AssumesBuy
 View More Analyst Ratings for SGMO

 View the Latest Analyst Ratings

read more...

Analyst Ratings for Sangamo Therapeutics

Sangamo Therapeutics GAAP EPS of -$0.66 misses by $0.32, revenue of $6.84M misses by $8.49M

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and second quarter 2023 financial results. I am extremely proud of our significant progress this quarter. We are pleased to have executed several business development deals...

Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2023 Financial Results

Sangamo Therapeutics Q2 2023 Earnings Preview

Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which comprises inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Brisbane, CA.

Watchers	10,849
52-Wk Low	$0.2911
52-Wk High	$3.76

Market Cap	$80.53M
Volume (M)	1.19M
52-Wk High	$3.76
52-Wk Low	$0.2911

SGMO Sangamo Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals

Sentiment

Message Volume

Community